Okklo life sciences BV is a privately held biopharmaceutical company developing novel therapeutic solutions using cyclodextrin-based technologies. 
The current programs are focussed on lysosomal storage disorders and cardiovascular disorders.

The company was founded in December 2011 by a group of life-sciences experts previously involved in the development and approval of sugammadex (Bridion™), the first modified cyclodextrin marketed as a drug product.

We are continuously looking for collaborations and partnering opportunities with public and private partners - please visit our website to learn more about our technology platform strategy and development pipeline.

Okklo Life Sciences

Org chart

Teams

Offices

Okklo Life Sciences

Org chart

Teams

Offices

Related companies